Pfizer Says Mid-November the Earliest It Can Seek FDA Approval for Coronavirus Vaccine

Pfizer Inc. will not seek emergency authorization of its coronavirus vaccine any earlier than the third week in November, when it projects it will hit important testing milestones, the company’s CEO said Friday.

In a letter posted on the company’s website, CEO Albert Bourla said that the vaccine must be first proven safe as well as effective before it is made available to the public.

“Safety is, and will remain, our number one priority, and we will continue monitoring and reporting safety data for all trial participants for two years,” Bourla wrote.

For a vaccine to qualify for emergency-use authorization by the Food and Drug Administration, trials must track at least half the participants in large-scale studies for two months after their second dose, the time period in which side effects could surface.

Bourla said his company’s trial will reach the two-month goal in November’s third week.

“We are operating at the speed of science,” he wrote.

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Adblock Detected

Please consider supporting us by disabling your ad blocker